Company intelligence / Profile preview
Oxilio
London, England, United Kingdomoxilio.co.uk ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Oxilio is conducting its first-in-human Phase 1 clinical trial of OXL001, an oral small molecule being repurposed for cancer, with the study designed to evaluate safety, tolerability and pharmacokinetics in patients with solid tumors.[4][5] Public sources do not yet report efficacy outcomes.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Quotient Sciences (development and clinical pharmacology services collaboration for OXL001, including formulation development and first-in-human study execution)
Beyond the preview
Go deeper on Oxilio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxilio.